RE:Where is the bottom? I think that the doubt about R+F business model these days is valid.
But I'm not very concerned about actual sales figures since I deem the objective of the deal is to get street cred for Sirona in order to show off to other players. I'm satisfied with a product on the market. Tick in the box.
However, the challenge that the management has created is to convince other players to pay a much needed premium compared to the lame deal with R+F.
A higher concentration or specialized compounds by skin type could be a possible strategy.
Hopefully they are able to nail a deal in China based on revenue split. That would be a game changer.
The real value in Sirona is represented by the upcoming anti-aging. I guess that they can act with better confidence by then, but are they at least on pair with by negotiating skills to get a decent deal? That's the big question I have.